Activity of fulvestrant versus exemestane in advanced breast cancer patients with or without visceral metastases: data from the EFECT trial
Authors:
- 23 November 2008
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 117 (1) , 69-75
Abstract
Purpose Patients with visceral metastases (VM: lung and/or liver metastases) are generally regarded as being less responsive to hormonal therapy, and chemotherapy often becomes the default treatment. This paper reports a subgroup analysis from EFECT (The Evaluation of Faslodex versus Exemestane Clinical Trial) examining the efficacy of fulvestrant and exemestane in patients with or without VM. Methods EFECT is a randomised, double-blind, multicentre, Phase III trial in postmenopausal women with advanced breast cancer progressing or recurring after prior non-steroidal aromatase inhibitor therapy. Results Overall, approximately 57% of patients in EFECT had visceral involvement. Fulvestrant and exemestane demonstrated clinical benefit in 29.1% and 27.2% of patients with VM, respectively. Median duration of response was 13.5 vs 10.8 months and median duration of clinical benefit was 9.9 vs 8.1 months, respectively. Conclusions These results encourage the use of endocrine agents such as fulvestrant in treating patients with advanced breast cancer and VM.Keywords
This publication has 13 references indexed in Scilit:
- Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor–Positive, Advanced Breast Cancer: Results From EFECTJournal of Clinical Oncology, 2008
- Fulvestrant (Faslodex™) in advanced breast cancer: clinical experience from a Belgian cooperative studyBreast Cancer Research and Treatment, 2007
- Clinical Evaluation of the Use of Exemestane as Further Hormonal Therapy after Nonsteroidal Aromatase Inhibitors in Postmenopausal Metastatic Breast Cancer PatientsCancer Investigation, 2007
- Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00)Annals of Oncology, 2006
- Exemestane in metastatic breast cancer: Effective therapy after third-generation non-steroidal aromatase inhibitor failureThe Breast, 2006
- Fulvestrant in Women With Advanced Breast Cancer After Progression on Prior Aromatase Inhibitor Therapy: North Central Cancer Treatment Group Trial N0032Journal of Clinical Oncology, 2006
- Third-Line Hormonal Treatment with Exemestane in Postmenopausal Patients with Advanced Breast Cancer Progressing on Letrozole or Anastrozole. A Phase II Trial Conducted by the Hellenic Group of Oncology (HELGO)Tumori Journal, 2006
- Fulvestrant (‘Faslodex’): Clinical experience from the Compassionate Use ProgrammeCancer Treatment Reviews, 2005
- A Review of the Efficacy of Anastrozole in Postmenopausal Women with Advanced Breast Cancer with Visceral MetastasesBreast Cancer Research and Treatment, 2003
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000